Press

Blackhawk and Mindbio Therapeutics Corp. (formerly, 1286409 B.C. LTD.) Announce Completion of Plan of Arrangement

May 2 • 3 min read

Blackhawk Growth Corp. (CSE: BLR / FSE: 0JJ) and MindBio Therapeutics Corp. (formerly, 1286409 B.C. Ltd.) are pleased to announce the completion of the previously announced plan of arrangement (the “Arrangement”) pursuant to which Blackhawk completed a spin-out of the common shares of MindBio . Arrangement As a result of the Arrangement, Blackhawk re-designated its issued and unissued…

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

May 2 • 7 min read

Incannex Healthcare Limited (Nasdaq: IXHL / ASX: IHL), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received final results from the Phase 1 clinical trial undertaken to assess pharmacokinetics and safety of the anti-inflammatory drug IHL-675A. IHL-675A is…

Update on Release of the 2022 Year End Financials and Board Of Directors

May 2 • 3 min read

Irwin Naturals Inc. (CSE: IWIN / OTC: IWINF / FRA: 97X) announces that the British Columbia Securities Commission has issued a failure-to-file-cease trade order (“CTO”) pursuant to National Policy 11-207 – Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions in respect of the securities of the Company as a result of the Company not having…

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

May 2 • 5 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF / CSE: PHRM), a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (“FDA”) for KETARX™ (ketamine) for the treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”). Fast Track designation aims to expedite the development and review of new drugs…

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

May 2 • 3 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an agreement with IMP Clinical Supply Services (“IMP”). IMP will be responsible for the global clinical supply chain of Clearmind’s proprietary drug candidate CMND-100…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436